In clinical studies, AUSTEDO® reduced tardive dyskinesia symptoms while people continued on their mental health medications.1-3

AUSTEDO® reduced the involuntary, repetitive, uncontrolled movements of TD in 2 clinical studies.

Study 1: Involuntary movement reduction at week 121

Study 1: Involuntary movement reduction at week 121

%
TAKING AUSTEDO®
vs
%
TAKING PLACEBO
AUSTEDO® (deutetrabenazine) tablets Clinical Study Reduced AIMS* Score Created with Sketch. placebo AUSTEDO ®
  • AUSTEDO® reduced the AIMS total score by
    3.3 points vs 1.4 points with placebo from the start of the study.
  • For participants taking AUSTEDO®, this represents a 33% reduction in AIMS total score vs a 12% reduction for those taking placebo.
  • Improvement in uncontrolled movements began to be seen at 2 weeks.

A reduction in AIMS total score means reduced involuntary movements.1,4

understanding aims

Study 2: Involuntary movement reduction at week 121

Study 2: Involuntary movement reduction at week 121

%
TAKING AUSTEDO®
vs
%
TAKING PLACEBO
AUSTEDO® (deutetrabenazine) tablets Clinical Study Created with Sketch. placebo AUSTEDO ®
  • AUSTEDO® reduced the AIMS total score by 3.0 points vs 1.6 points with placebo.
  • This represents an approximately 27% reduction in AIMS total score for people taking AUSTEDO® vs a 16% reduction for those taking placebo.

Download the Doctor Discussion Guide

This resource can help you and your doctor decide if AUSTEDO® is right for you.

You are about to leave this site

You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.

Are you a healthcare professional?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?

References: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Teva Pharmaceuticals USA, Inc. 2. Data on file. Teva Neuroscience, Inc. 3. Warikoo N, Schwartz T, Citrome L. Tardive dyskinesia. In: Aguilar, M, ed. Antipsychotic Drugs: Classification, Pharmacology and Long-Term Health Effects. Hauppauge, NY: Nova Science Publishers, Inc; 2013:235-258. 4. Abnormal Involuntary Movements Scale (AIMS) – overview. Center for Quality Assessment and Improvement in Mental Health website. http://www.cqaimh.org/pdf/tool_aims.pdf. Accessed September 4, 2019.